Eli Lilly released new data from a study of its obesity drug Tirzepatide
因醉鞭名马幌
发表于 2023-10-4 13:30:04
154
0
0
SURMOUNT-CN Phase III clinical study results showed that obese and overweight Chinese adults treated with Tirzepatide experienced up to 19.9% weight loss from baseline at week 52. The proportion of participants in the Tirzepatide 15mg group who achieved weight loss of ≥5% (one of the co-primary endpoints) was 92.7%.
Lilly said the overall safety profile of Tirzepatide in the SURMOUNT-CN trial was similar to that reported in previous trials, and no new safety signals were found. The most commonly reported intratreatment adverse events in the Tirzepatide group were gastrointestinal adverse events, which were mostly mild to moderate in severity and occurred primarily during dose escalation.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Anonymous processing of facial information outside the car, default not to collect cabin data Tesla meets automotive data security compliance requirements! Various regions have gradually lifted restrictions on travel
- A milestone breakthrough! Google DeepMind launches a new generation of drug development AI model AlphaFold 3
- European drug regulatory agency recommends approval of Dupixen for the treatment of patients with chronic obstructive pulmonary disease
- "Never go against the Federal Reserve"? NO! Currently, Wall Street is more inclined to oppose data and bias
- Smegglutide has been approved for the treatment of obesity in China, with a supply chain gap of over 70 billion US dollars in the market
- Will Smegglutide's indications for treating obesity participate in this year's national medical insurance negotiations? Novo Nordisk responded by stating that they will immediately initiate internet access and hospital admissions in various regions
- Eisai/Bojian Alzheimer's disease drug rejected by the European Union, and Eli Lilly monoclonal antibody may be affected
- AstraZeneca's market value has surpassed £ 200 billion for the first time! The bold bet on anti-cancer drugs is yielding results
- Bristol Myers Squibb's original tumor treatment drug Abraxane has been officially launched in China
- LeXin releases consumer protection report: 148 million data security attacks intercepted within the year
-
【世界市場】1、納指は0.04%、ダウは0.70%、スタンダードは0.19%下落した。2、英偉達は2%超上昇し、美光科技の株価は10%超上昇した。3、ナスダック中国の金龍指数は2.80%、蔚来は5%近く下落した。4、国際原油価格は ...
- 虚空一粒沙2017
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
世界的な整形外科大手のシュレックはこのほど、ニューラルテクノロジー会社のNico Corporationの買収を完了したと発表した。紹介によると、Nicoは私営会社で、腫瘍と脳内出血(ICH)手術のための系統的な低侵襲手術 ...
- 就放荡不羁就h
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
AP通信9月27日、インテルは今月中旬に発表された重大な業務調整に加え、近日中にクアルコムに買収合併される可能性があるとの情報を伝えていることを明らかにした。 しかし、ウォール街のほとんどのアナリストは、 ...
- 什么大师特
- 前天 16:13
- 支持
- 反对
- 回复
- 收藏
-
9月26日、Meta Platformsは巨額の資金を投じてスターを招待していることを明らかにした。Metaは水曜日、俳優のオスカー・フィーナ(Awkwafina)、ジョン・セナ(John Cena)、ジュディ・デンチ(Judi Dench)、クリ ...
- hecgdge4
- 3 天前
- 支持
- 反对
- 回复
- 收藏